KR20130013856A - Composition for anti-obesity or reducing body fat, containg meja-treated buckwheat sprout - Google Patents
Composition for anti-obesity or reducing body fat, containg meja-treated buckwheat sprout Download PDFInfo
- Publication number
- KR20130013856A KR20130013856A KR1020110075738A KR20110075738A KR20130013856A KR 20130013856 A KR20130013856 A KR 20130013856A KR 1020110075738 A KR1020110075738 A KR 1020110075738A KR 20110075738 A KR20110075738 A KR 20110075738A KR 20130013856 A KR20130013856 A KR 20130013856A
- Authority
- KR
- South Korea
- Prior art keywords
- obesity
- body fat
- composition
- treated
- buckwheat
- Prior art date
Links
- 241000219051 Fagopyrum Species 0.000 title claims abstract description 54
- 235000009419 Fagopyrum esculentum Nutrition 0.000 title claims abstract description 54
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 32
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- GEWDNTWNSAZUDX-UHFFFAOYSA-N Jasmonic Acid Methyl Ester Chemical compound CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 claims abstract description 31
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 25
- 230000009467 reduction Effects 0.000 claims abstract description 20
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 claims abstract description 17
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- ZNJFBWYDHIGLCU-UHFFFAOYSA-N jasmonic acid Natural products CCC=CCC1C(CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 6
- 238000012364 cultivation method Methods 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 235000013376 functional food Nutrition 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 4
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 항비만 또는 체지방감소를 위한 조성물에 관한 것이다. 본 발명은 또한 항비만 또는 체지방감소 방법에 관한 것이다. 본 발명은 또 메밀새싹의 항비만 효과를 높이는 재배 방법에 관한 것이다.
The present invention relates to a composition for anti-obesity or body fat reduction. The invention also relates to a method of anti-obesity or body fat reduction. The present invention also relates to a cultivation method for enhancing the anti-obesity effect of buckwheat sprout.
2006년 기준으로 세계적인 비만인구는 2억 5천만명에 달하며, 한국의 비만인구도 1995년 11.7%(남), 18.0%(여)이었으나, 2001년에는 각각 26.5%, 25.9%로 증가하고 있다. 비만치료제 국내시장은 의약품으로만 2009년 기준 약 1000억에 달하며, 매년 약 20%의 성장률을 보이고 있으며, 또한, 건강기능식품, 비만개선에 유용한 식품 등의 시장규모는 의약품 규모를 훨씬 능가할 것으로 판단된다.As of 2006, the world's obesity population was 250 million, and Korea's obesity population was 11.7% in South Korea and 18.0% in 1995, but it increased to 26.5% and 25.9% in 2001, respectively. The domestic market for obesity drugs alone is about 100 billion won in 2009, and the annual growth rate is about 20%, and the market size of health functional foods and foods useful for improving obesity will far exceed the size of medicines. Judging.
이러한 비만을 개선하기 위한 약물로서는 식욕을 억제하는 약물인 시부트라민(sibutramine)과 체내의 리파제(lipase)를 억제하여 음식물에 포함된 지방질의 흡수를 감소시키는 올리스타트(orlistat)가 대표적이다.Such drugs for improving obesity include sibutramine, a drug that suppresses appetite, and orlistat, which suppresses the absorption of fat contained in food by inhibiting lipase in the body.
그러나 시부트라민의 경우 혈압상승, 불면증, 구강건조, 어지러움 등의 부작용이 비교적 흔하다. 또한 시부트라민은 심혈관질환, 조절되지 않는 고혈압을 가진 환자에게 나타나는 부작용이 매우 커서 식품의약품안전청으로부터 그 허가가 취소되었다. 또 올리스타트의 경우에는 설사, 지방변, 분실금 등의 부작용이 흔하고 한국인과 같이 지방 섭취가 서양인에 비해 적은 경우에는 약물의 효과가 뚜렷하지 않다. However, in the case of sibutramine, side effects such as blood pressure rise, insomnia, dry mouth, and dizziness are relatively common. In addition, sibutramine was revoked from the Food and Drug Administration due to its high side effects in patients with cardiovascular disease and uncontrolled hypertension. In the case of olistat, side effects such as diarrhea, fatty stool, and loss money are common, and the effect of the drug is not obvious when the fat intake is less than that of Westerners such as Koreans.
따라서 더욱 안전하면서도 항비만 효과 및 체지방감소 효과가 탁월한 약물에 대한 꾸준한 연구의 필요성이 제기되고 있으며, 특히 오랫동안 복용되어 안전성이 입증된 식물, 생약재 등으로 유효성분을 얻고자 하는 노력이 활발하다.
Therefore, the need for steady research on drugs that are safer and excellent in anti-obesity effect and body fat reduction effect has been raised. Especially, efforts are being made to obtain active ingredients with plants, herbal medicines, etc., which have been taken for a long time and proven safe.
따라서 본 발명이 이루고자 하는 기술적 과제는 부작용이 적어 안전하면서도 항비만 및/또는 체지방감소 효과가 뛰어난 조성물 및 이를 함유하는 의약품 또는 기능성 식품을 제공하는 것이다.Therefore, the technical problem to be achieved by the present invention is to provide a composition having a low side effect and excellent in anti-obesity and / or body fat reduction effect and a pharmaceutical or functional food containing the same.
본 발명이 이루고자 하는 다른 기술적 과제는 안전하면서도 효과적인 항비만 및/또는 체지방감소 방법을 제공하는 것이다.
Another technical problem to be achieved by the present invention is to provide a safe and effective anti-obesity and / or body fat reduction method.
상기 기술적 과제를 달성하기 위하여, 본 발명은 자스모닉산(jasmonic acid, JA) 또는 메틸자스모네이트(methyl jasmonate, MeJA)로 처리되어, 더욱 바람직하게는 메틸자스모네이트로 처리되어 재배된 메밀새싹, 이의 분쇄물 또는 이의 추출물을 유효성분으로 포함하는 것을 특징으로 하는 비만 개선 또는 체지방감소용 조성물을 제공한다.In order to achieve the above technical problem, the present invention is treated with jasmonic acid (jasmonic acid, JA) or methyl jasmonate (methyl jasmonate, MeJA), more preferably treated with methyl jasmonate buckwheat sprout It provides a composition for improving obesity or reducing body fat, comprising a pulverized product or extract thereof as an active ingredient.
본 발명은 MeJA 등으로 처리한 메밀싹기름채소 추출물은 통상적인 재배수로 재배한 메밀싹기름채소 추출물 대비 3T3-L1 지방세포의 분화 억제 효능이 더 높아 세포 내 지방축적을 감소시키는데 더욱 효과적이었으며, 지방세포 분화와 연관된 세포 내 주요 전사인자들의 발현을 억제하는 정도 또한 통상적인 재배수로 재배한 메밀싹기름채소 대비 월등히 높다는 놀라운 사실에 기초한다.In the present invention, the buckwheat sprout oil extract treated with MeJA and the like was more effective in reducing the accumulation of intracellular fat due to the higher inhibitory effect of differentiation of 3T3-L1 adipocytes than the buckwheat sprout oil extract grown in conventional cultivation water. The degree of inhibition of the expression of major transcription factors in cells associated with adipocyte differentiation is also based on the surprising fact that it is significantly higher than buckwheat sprouts grown in conventional cultivation.
또한, 지방세포 분화와 연관된 주요 전사인자들에 미치는, 메밀의 주요 성분인 루틴(rutin)에 의한 영향은 상대적으로 미비하였다. 이러한 결과로부터 MeJA 등으로 처리된 메밀새싹 중 항비만 또는 체지방감소 효과를 나타내는 주요 활성성분으로 루틴 이외의 다른 성분이 종합적으로 그 역할을 하는 것으로 추측되나, 본 발명은 이러한 이론적 기전에 한정되는 것은 아니다.In addition, the effects of rutin, a major component of buckwheat, on major transcription factors associated with adipocyte differentiation were relatively insignificant. From these results, it is speculated that buckwheat sprouts treated with MeJA, etc., play an important role as a main active ingredient that exhibits anti-obesity or body fat reduction effect. .
본 발명은 또한 상기 조성물을 포함하는 것을 특징으로 하는 항비만 및/또는 체지방감소용 의약품 또는 기능성 식품을 제공한다.The present invention also provides a pharmaceutical or functional food for anti-obesity and / or body fat reduction, comprising the composition.
본 발명자들은 오랫동안 사용되어 안전성이 입증된 천연물 중에서 항비만 및 체지방감소 효과를 가지는 조성물을 얻고자 노력하였고, JA 또는 MeJA이 첨가된 재배수로 재배된 메밀새싹(메밀싹기름채소)가 뛰어난 항비만 및 체지방감소 효과가 있음을 확인하여 본 발명을 완성하였다.The present inventors endeavored to obtain a composition having anti-obesity and body fat-reducing effects among natural products that have been used for a long time and have proven safety, and have excellent anti-obesity with buckwheat sprouts (buckwheat sprout oil vegetable) grown with cultivated water added with JA or MeJA. And confirmed that the body fat reduction effect has been completed the present invention.
본 발명의 항비만 및/또는 체지방감소용 건강기능식품 또는 의약품에 포함되는 유효성분은 메밀새싹 그 자체일 수 있으며, 메밀새싹의 건조물, 분쇄물 또는 메밀새싹의 추출물일 수 있다.The active ingredient included in the anti-obesity and / or body fat-reducing health functional food or drug of the present invention may be the buckwheat sprout itself, and may be an extract of the dried, ground or buckwheat sprout of the buckwheat sprout.
메밀새싹의 건조물 및 분쇄물은 본 발명이 속한 분야에서 잘 알려진 방법들을 이용하여 제조될 수 있다. 예를 들어, 통풍(자연풍) 건조, 열풍 건조, 동결 건조 등의 방법으로 건조물이 제조될 수 있으며, 통상적인 분쇄기를 이용하여 분말 상의 분쇄물을 제조할 수 있다.Dried and crushed buckwheat sprouts can be prepared using methods well known in the art. For example, a dry matter may be manufactured by a method such as ventilation (natural wind) drying, hot air drying, freeze drying, or the like, and a powdery powder may be manufactured using a conventional mill.
메밀새싹의 추출물은 본 발명이 속한 분야에서 잘 알려진 추출 방법을 통해서 얻을 수 있다. 예를 들어, 추출용매로는 정제수; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 탄소수 1 내지 4의 저급 알코올; 글리세린, 부틸렌글라이콜, 프로필렌글라이콜 등의 다가 알코올; 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들은 혼합 용매를 이용할 수 있다. The extract of buckwheat sprout can be obtained through an extraction method well known in the art. For example, the extractant may be purified water; Lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; Hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether and dichloromethane; Or these can use a mixed solvent.
보다 구체적으로, 예를 들어, 메밀새싹을 음건하여 분쇄한 후, 추출용매를 메밀새싹의 1 내지 20배 부피량 만큼 가하여 추출하고 나서, 선택적으로 (감압)농축, 건조 또는 정제 과정을 거쳐 제조할 수 있다. 보다 구체적으로, 전술한 방법과 같이 추출용매를 가하여 유효성분물질을 추출하되 (a) 냉각 콘덴서가 장치되어 용매가 증발되는 것을 방지한 상태에서 50 내지 100℃의 온도 조건에서 1 내지 20시간 가열하여 추출하거나, (b) 5 내지 37℃의 온도 조건에서 1 내지 15일간 침적시켜 유효성분을 추출할 수 있다. 즉, 교반 추출, 환류 냉각 추출, 냉침 추출, 초음파 추출 또는 초임계 추출 등의 추출방법을 사용하여 제조할 수 있다.
More specifically, for example, the buckwheat sprout may be dried and pulverized, followed by extracting the extractant by adding 1 to 20 times the volume of the buckwheat sprout, and then selectively (decompression) concentration, drying or purification to prepare the process. Can be. More specifically, the active ingredient material is extracted by adding an extraction solvent as described above (a) by heating for 1 to 20 hours at a temperature of 50 to 100 ℃ in a state that the cooling condenser is installed to prevent the solvent from evaporating Extraction or (b) may be performed by dipping for 1 to 15 days at 5 to 37 ℃ temperature conditions to extract the active ingredient. That is, it can manufacture using extraction methods, such as stirring extraction, reflux cooling extraction, cold needle extraction, ultrasonic extraction, or supercritical extraction.
본 발명의 항비만 또는 체지방감소용 조성물은 의약품 및 기능성 식품의 형태로 제조될 수 있다. 이러한 의약품 및 기능성 식품은 약제학적으로 허용되는 부형제 또는 첨가제를 포함할 수 있다. 본 발명의 항비만 또는 체지방감소용 조성물은 단독으로 혹은 어떤 편리한 운반체, 부형제 등과 함께 혼합하여 투여될 수 있고, 그러한 투여 제형은 단회투여 또는 반복투여 제형일 수 있다.The anti-obesity or body fat reducing composition of the present invention can be prepared in the form of pharmaceuticals and functional foods. Such medicaments and functional foods may include pharmaceutically acceptable excipients or additives. The anti-obesity or body fat reducing composition of the present invention may be administered alone or in admixture with any convenient carrier, excipient, etc., and such dosage forms may be single or repeated dose formulations.
본 발명의 항비만 또는 체지방감소용 조성물을 포함하는 의약품 또는 기능성 식품은 고형 제제 또는 액상 제제일 수 있다. 고형 제제는 산제, 과립제, 정제, 캅셀제, 좌제 등이 있으나, 이에 한정되는 것은 아니다. 고형 제제에는 부형제, 착향제, 결합제, 방부제, 붕해제, 활택제, 충진제 등이 포함될 수 있으나 이에 한정되는 것은 아니다. 액상 제제로는 물, 프로필렌 글리콜 용액 같은 용액제, 현탁액제, 유제 등이 있으나, 이에 한정되는 것은 아니며, 적당한 착색제, 착향제, 안정화제, 점성화제 등을 첨가하여 제조할 수 있다.The pharmaceutical or functional food comprising the anti-obesity or body fat reducing composition of the present invention may be a solid preparation or a liquid preparation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid form preparations may include, but are not limited to, excipients, flavors, binders, preservatives, disintegrants, lubricants, fillers and the like. Liquid formulations include, but are not limited to, solutions such as water, propylene glycol solutions, suspensions, emulsions, and the like, and may be prepared by adding suitable colorants, flavors, stabilizers, viscosity agents, and the like.
예를 들어, 산제는 본 발명의 메밀새싹 분쇄물 또는 추출물과 유당, 전분, 미결정셀룰로오스 등 약제학적으로 허용되는 적당한 부형제를 단순 혼합함으로써 제조될 수 있다. 과립제는 본 발명의 메밀새싹 분쇄물 또는 추출물; 약제학적으로 허용되는 적당한 부형제; 및 폴리비닐피롤리돈, 히드록시프로필셀룰로오스 등의 약제학적으로 허용되는 적당한 결합제를 혼합한 후, 물, 에탄올, 이소프로판올 등의 용매를 이용한 습식과립법 또는 압축력을 이용한 건식과립법을 이용하여 제조될 수 있다. 또한 정제는 상기 과립제를 마그네슘스테아레이트 등의 약제학적으로 허용되는 적당한 활택제화 혼합한 후, 타정기를 이용하여 타정함으로써 제조될 수 있다.For example, powders may be prepared by simply mixing the buckwheat sprout mill or extract of the present invention with a suitable pharmaceutically acceptable excipient such as lactose, starch, microcrystalline cellulose. Granules are buckwheat sprouts or extracts of the present invention; Pharmaceutically acceptable excipients; And a pharmaceutically acceptable binder such as polyvinylpyrrolidone and hydroxypropyl cellulose, and then prepared by using a wet granulation method using a solvent such as water, ethanol, isopropanol, or a dry granulation method using a compressive force. Can be. Tablets may also be prepared by mixing the granules with a suitable pharmaceutically acceptable glidant such as magnesium stearate and then tableting using a tableting machine.
항비만 또는 체지방감소라는 본 발명의 목적을 달성하기 위하여 메밀새싹 분쇄물 또는 추출물은 매일 약 0.01 mg/kg 내지 약 5 g/kg이 투여될 수 있으며, 약 0.1 mg/kg 내지 약 1 g/kg의 1일 투여 용량이 바람직하다. 그러나 상기 투여량은 환자의 상태(연령, 성별, 체중 등), 치료하고 있는 상태의 심각성 등에 따라 다양할 수 있다. 필요에 따라 편리성을 위하여 1일 총 투여량이 나누어지고 하루 동안 여러 번 나누어 투여될 수 있다.
Buckwheat sprouts or extracts may be administered daily from about 0.01 mg / kg to about 5 g / kg, and from about 0.1 mg / kg to about 1 g / kg, in order to achieve the object of the present invention called anti-obesity or body fat reduction. Daily doses of are preferred. However, the dosage may vary depending on the condition of the patient (age, sex, weight, etc.), the severity of the condition being treated, and the like. If desired, the total daily dose may be divided for convenience and divided several times throughout the day.
본 발명은 또한 메밀새싹, 이의 건조물, 분쇄물 또는 추출물을 투여하는 것을 포함하는 항비만, 체중유지 또는 체지방감소 방법을 제공한다.The present invention also provides a method for anti-obesity, weight maintenance or body fat reduction, comprising administering buckwheat sprout, dried product, ground product or extract thereof.
본 발명은 또한 본 발명에 따른 조성물을 체중감소 또는 체지방감소가 필요한 개체에게 투여하는 것을 포함하는 항비만 및/또는 체지방감소 방법을 제공한다.
The invention also provides a method of anti-obesity and / or body fat reduction comprising administering a composition according to the invention to a subject in need of weight loss or body fat loss.
본 발명은 또한 자스모닉산(jasmonic acid) 또는 메틸자스모네이트(methyl jasmonate)로 처리하는 것을 특징으로 하는, 보다 바람직하게는 메밀자스모네이트로 처리하는 것을 특징으로 하는 메밀새싹의 항비만 또는 체지방감소 효과를 높이는 재배 방법을 제공한다.The present invention also provides anti-obesity or body fat of buckwheat sprouts, characterized by treatment with jasmonic acid or methyl jasmonate, more preferably with buckwheat jasmonate. Provide a cultivation method that increases the reduction effect.
예를 들어, 상기 JA 또는 MeJA는 재배수에 약 0.01-200 mM, 바람직하게는 0.05-2 mM의 농도로, 더욱 바람직하게는 0.08-0.5 mM의 농도로 첨가된다. 만일 0.01 mM 농도 이하로 첨가될 경우 첨가에 따른 항비만/체지방감소 효과의 개선 정도가 크지 않고, 200 mM을 초과하여 처리할 경우 오히려 메밀새싹의 생육저하를 초래할 염려가 있다. 이러한 재배수를 1-3일에 1번 정도로 1회 50 mL-4 L/m2씩 공급하여 재배할 수 있다. 보다 바람직하게, 메밀 종자의 발아(재배) 과정에서 메틸자스모네이트를 0.1 mM 농도로 1일 1회 100 mL씩 첨가하여 재배할 수 있다.
For example, the JA or MeJA is added to the planting water at a concentration of about 0.01-200 mM, preferably 0.05-2 mM, more preferably at a concentration of 0.08-0.5 mM. If it is added below 0.01 mM concentration, the antiobesity / body fat reduction effect of the addition is not large, and if the treatment exceeds 200 mM there is a fear that the growth of buckwheat sprout. Such cultivation water can be cultivated by feeding 50 mL-4 L / m 2 once per 1-3 days. More preferably, during the germination (cultivation) of buckwheat seeds, methyl jasmonate can be grown by adding 100 mL once daily at a concentration of 0.1 mM.
본 발명은 자스모닉산 또는 메틸자스모네이트로 처리되어 재배된 메밀새싹, 이의 건조물, 분쇄물 또는 추출물의 항비만 또는 체지방감소 용도를 제공한다. 본 발명에 따른 의약품 또는 기능성 식품은 항비만 또는 체지방감소 효과가 탁월하다. 또한, 본 발명은 메밀새싹의 항비만 또는 체지방감소 효과를 높이는 재배 방법을 제공한다.
The present invention provides an anti-obesity or body fat reduction use of buckwheat sprouts, their dried products, ground products or extracts which have been treated with jasmonic acid or methyljasmonate. Medicines or functional foods according to the present invention is excellent in anti-obesity or body fat reduction effect. The present invention also provides a cultivation method for enhancing the anti-obesity or body fat reduction effect of buckwheat sprout.
도 1은 메밀새싹 추출물이 3TC-L1 전지방세포의 지방 축적에 미치는 영향을 분석한 결과이다.
도 2는 메밀새싹 추출물이 지방세포 분화와 연관된 전사인자인 C/EBPα (CCAAT/enhancer binding protein α) 및 타깃 유전자인 aP2 (adipocyte protein 2)의 발현에 미치는 영향을 분석한 결과이다.1 is a result of analyzing the effect of buckwheat sprout extract on the fat accumulation of 3TC-L1 cells.
2 is a result of analyzing the effect of buckwheat sprout extract on the expression of C / EBPα (CCAAT / enhancer binding protein α), a transcription factor associated with adipocyte differentiation, and aP2 (adipocyte protein 2), a target gene.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.
Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
<실시예 1> MeJA 처리 메밀새싹의 재배Example 1 Cultivation of MeJA-treated Buckwheat Sprouts
본 실험에 메밀은 봉평에서 2008년에 재배된 종자를 구입하여 새싹재배기(Mikrofarm, EasyGreen Co., MA, USA)를 이용하여 1일 4회 (15분간) 분주하도록 설정한 후 7일간 일정온도에서 성장시켰다. 성장 중 abiotic 처리로서 메틸 자스모네이트(MeJA)를 0.1 mM 농도로 1일 1회 100 mL씩 첨가적으로 분주하였다. 메밀새싹은 뿌리부분을 제외한 줄기이상의 부분을 절단한 후 -70℃의 온도에서 동결한 후 동결건조기를 이용하여 건조하고 blender (KA-2600, Kaiser, Korea) 로 분쇄한 후 60mesh (850mm2) 표준망에 통과시켜 추출 시료로 사용하였다.
In this experiment, buckwheat was purchased from Bongpyeong in 2008 and set to dispense four times a day (15 minutes) using a sprout cultivator (Mikrofarm, EasyGreen Co., MA, USA). Grown. As abiotic treatment during growth, methyl jasmonate (MeJA) was additionally dispensed 100 mL once daily at a concentration of 0.1 mM. The buckwheat sprout is cut at the part above the stem except for the root part, frozen at -70 ℃, dried using a lyophilizer, crushed with a blender (KA-2600, Kaiser, Korea), and then 60mesh (850mm 2 ) standard. It was passed through a network and used as an extract sample.
<실시예 2> MeJA 처리 메밀새싹 추출물의 제조Example 2 Preparation of MeJA-treated Buckwheat Sprout Extract
하기 실험예에서 사용한 추출물들은 다음과 같이 제조하였다. 실시예 1에서 재배한 메밀쌔싹을 MeJA 처리구와 비처리구로 구분한 후 동결건조하였다. 이후 이에 80 중량% 에탄올 5배수를 가한 다음, 3시간 동안 20℃에서 3회 반복 추출하였다. 이를 10,000 × g에서 15분간 원심 분리하여 상층액을 여과한 후 동결건조하여 추출물 시료로 제조하였다.
The extracts used in the following experimental examples were prepared as follows. The buckwheat sprouts grown in Example 1 were divided into MeJA and non-treated groups, and then lyophilized. Thereafter, 80 wt% ethanol 5 times was added thereto, and then extracted three times at 20 ° C. for 3 hours. This was centrifuged at 10,000 x g for 15 minutes to filter the supernatant and then lyophilized to prepare an extract sample.
<실험예 1> 3T3-L1 지방세포의 분화과정에서의 세포 내 지방축적량Experimental Example 1 Intracellular Adipose Accumulation During Differentiation of 3T3-L1 Adipocytes
3T3-L1 지방세포의 분화과정에서의 메밀싹기름채소 추출물들에 의한 세포 내 지방축적량을 비교한 결과를 도 1에 나타내었다.The results of comparing the amount of intracellular fat accumulation by the buckwheat sprout oil extracts during the differentiation of 3T3-L1 adipocytes are shown in FIG. 1.
3T3-L1 전지방세포에 세포분화 유도물질을 처리하고 메밀싹기름채소 추출물들을 각각 100 ㎍/mL씩 처리하여 8일간 지방세포로 분화하였으며 분화된 지방세포에 축적된 지방의 함량은 Oil red O staining 방법을 이용하여 측정하였다. 구체적으로, 염색된 Oil red O (lipid accumulation)는 용해되었고 490 nm에서 흡광도가 측정되었다. 각 값은 6개의 다른 플레이트 (n=6)의 평균과 표준편차이다. One-way ANOVA (p<0.05)를 이용하여 통계 처리를 하였다.Cells were treated with 3T3-L1 cells to induce cell differentiation, and buckwheat sprout oil extracts were treated with 100 ㎍ / mL each to differentiate into adipocytes for 8 days. The amount of fat accumulated in the differentiated adipocytes was oil red O staining. It was measured using the method. Specifically, the stained Oil red O (lipid accumulation) was dissolved and the absorbance was measured at 490 nm. Each value is the mean and standard deviation of six different plates (n = 6). Statistical treatment was performed using One-way ANOVA ( p <0.05).
도 1에 나타나는 바와 같이, 지방세포의 분화과정 동안 대조군의 3T3-L1 세포에는 다량 lipid drop을 세포 내에 축적하는 것으로 나타났다. 메밀싹기름채소 추출물, 0.1 mM MeJA 처리한 메밀싹기름채소 추출물 및 루틴 (메밀싹기름채소 주요성분)을 100 ㎍/mL 처리한 결과, 대조군에 비해 지방세포의 지방축적이 감소하는 경향을 나타내었으며, 특히 0.1 mM MeJA 처리한 메밀싹기름채소 추출물을 처리한 지방세포의 lipid drop 생성의 억제능이 가장 강한 것으로 나타났다.
As shown in Figure 1, during the differentiation of adipocytes, 3T3-L1 cells of the control group was found to accumulate a large amount of lipid drop in the cells. When 100 ㎍ / mL of buckwheat sprout oil extract, buckwheat sprout oil extract treated with 0.1 mM MeJA and rutin (the main ingredient of buckwheat sprout oil) were treated, the fat accumulation of fat cells was decreased as compared with the control. In particular, it showed the strongest inhibitory effect of lipid drop formation in adipocytes treated with 0.1 mM MeJA-treated buckwheat sprout oil extract.
<실험예 2> 지방세포 분화와 연관된 전사인자인 C/EBPa 및 타깃 유전자인 aP2의 발현에 미치는 영향 검토<Experiment 2> Examination of the effect on the expression of transcription factor C / EBPa and target gene aP2 associated with adipocyte differentiation
본 실험에서는 메밀싹기름채소 추출물 및 0.1 mM MeJA 처리한 메밀싹기름채소 추출물의 항비만 활성에 대한 mRNA 수준에서의 작용기작을 살펴보았다. 즉, 3T3-L1 세포 내 지방축적 억제효과에 대한 작용기전을 알아보고자 지방세포 분화와 연관된 전사인자인 C/EBPα (CCAAT/enhancer binding protein α) 및 타깃 유전자인 aP2 (adipocyte protein 2)의 발현에 미치는 영향을 살펴보았으며 그 결과를 도 2에 나타내었다.In this experiment, we investigated the mechanism of action on mRNA levels of anti-obesity activity of buckwheat sprout oil extract and 0.1 mM MeJA-treated buckwheat sprout oil extract. In other words, to investigate the mechanism of action of fat accumulation inhibitory effect in 3T3-L1 cells, expression of C / EBPα (CCAAT / enhancer binding protein α), a transcription factor associated with adipocyte differentiation, and aP2 (adipocyte protein 2), a target gene, were expressed. The effect was examined and the results are shown in FIG. 2.
처리 8일째, RNA prep kit 등을 이용하는 통상적인 방법으로 총 세포 RNA가 추출되었으며, RT-PCR를 수행하였다. 대조군 유전자로 GAPDH 유전자를 사용하여 CEBPα 및 aP2 mRNA의 레벨을 정량하였다. 밴드 강도는 Image J program을 사용하여 정량하였다. 사용된 포워드 프라이머 및 리버스 프라이머는 하기 표 1과 같다.On the eighth day of treatment, total cellular RNA was extracted by a conventional method using an RNA prep kit and the like, and RT-PCR was performed. GAPDH gene was used as a control gene to quantify the levels of CEBPα and aP2 mRNA. Band intensities were quantified using Image J program. The forward primers and reverse primers used are shown in Table 1 below.
도 2에 나타나는 바와 같이, 0.1 mM MeJA를 처리한 메밀싹기름채소 추출물(TBWE)을 10 ㎍/ml의 농도로 처리한 지방세포의 C/EBPα 및 aP2 mRNA의 발현은 대조군 대비 감소하는 경향을 나타낸 반면, 루틴을 처리한 지방세포의 C/EBPα 및 aP2 mRNA 는 대조군과 유사한 발현 양을 나타내었다. 이러한 결과는 0.1 mM MeJA를 처리한 메밀싹기름채소 추출물에 함유된 루틴은 지방세포 내 주요 전사인자의 발현에 영향을 미치지 못하였으며, 0.1 mM MeJA를 처리한 메밀싹기름채소 추출물의 항비만 활성은 루틴의 작용기전과는 다른 것으로 사료되었다. 또한, MeJA 처리를 하지 않은 메밀싹기름채소 추출물(NBWE)의 경우에도 농도를 높여 처리할 경우(예를 들어, 100 ㎍/ml) C/EBPα 및 aP2 mRNA의 발현이 대조군 대비 줄어드는 경향을 나타내었으나, 그 정도는 본 발명에 따른 MeJA를 처리한 메밀싹기름채소 추출물에 비해 미약하였다.As shown in FIG. 2, C / EBPa and aP2 mRNA expression of adipocytes treated with 0.1 mM MeJA-treated buckwheat sprout vegetable extract (TBWE) at a concentration of 10 μg / ml showed a tendency to decrease compared to the control group. In contrast, C / EBPa and aP2 mRNAs of adipocytes treated with rutin showed similar expression levels as control. These results indicate that rutin contained in buckwheat sprout oil extracts treated with 0.1 mM MeJA did not affect the expression of major transcription factors in adipocytes. It seems to be different from rutin's mechanism of action. In addition, in the case of buckwheat sprout vegetable extract (NBWE) not treated with MeJA, the expression of C / EBPa and aP2 mRNA was decreased in the case of increasing the concentration (for example, 100 ㎍ / ml) compared with the control group. The degree was weak compared to buckwheat sprout oil vegetable extract treated with MeJA according to the present invention.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110075738A KR101282708B1 (en) | 2011-07-29 | 2011-07-29 | Composition for Anti-Obesity or Reducing Body Fat, Containg MeJA-Treated Buckwheat Sprout |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110075738A KR101282708B1 (en) | 2011-07-29 | 2011-07-29 | Composition for Anti-Obesity or Reducing Body Fat, Containg MeJA-Treated Buckwheat Sprout |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130013856A true KR20130013856A (en) | 2013-02-06 |
KR101282708B1 KR101282708B1 (en) | 2013-07-05 |
Family
ID=47894254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110075738A KR101282708B1 (en) | 2011-07-29 | 2011-07-29 | Composition for Anti-Obesity or Reducing Body Fat, Containg MeJA-Treated Buckwheat Sprout |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101282708B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101525143B1 (en) * | 2013-07-05 | 2015-06-02 | 한국식품연구원 | Method for increasing glucosinolate content of radish sprouts |
KR20190075544A (en) * | 2017-12-21 | 2019-07-01 | 제주특별자치도서귀포시 | Method of cultivation of buckwheat sprout with enhanced phenolic compound content by treating jasmonic acid |
KR20210019915A (en) | 2019-08-13 | 2021-02-23 | 코스맥스바이오 주식회사 | Functional health food composition for Preventing and Improving Obesity and metabolic disease fermented fagopyrum tataricum extract |
WO2024090929A1 (en) * | 2022-10-24 | 2024-05-02 | 농업회사법인 주식회사 넥스트온 | Composition for inhibiting fat accumulation, containing cassia seed sprout and buckwheat sprout |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102326641B1 (en) | 2019-06-25 | 2021-11-17 | 주식회사 현대바이오랜드 | Composition comprising extract of buckwheat sprout for strengthening hair root, activating hair growth or preventing alopecia |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100907686B1 (en) * | 2007-10-31 | 2009-07-14 | 한국식품연구원 | Anti-obesity foods containing germinated buckwheat extract |
-
2011
- 2011-07-29 KR KR1020110075738A patent/KR101282708B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101525143B1 (en) * | 2013-07-05 | 2015-06-02 | 한국식품연구원 | Method for increasing glucosinolate content of radish sprouts |
KR20190075544A (en) * | 2017-12-21 | 2019-07-01 | 제주특별자치도서귀포시 | Method of cultivation of buckwheat sprout with enhanced phenolic compound content by treating jasmonic acid |
KR20210019915A (en) | 2019-08-13 | 2021-02-23 | 코스맥스바이오 주식회사 | Functional health food composition for Preventing and Improving Obesity and metabolic disease fermented fagopyrum tataricum extract |
WO2024090929A1 (en) * | 2022-10-24 | 2024-05-02 | 농업회사법인 주식회사 넥스트온 | Composition for inhibiting fat accumulation, containing cassia seed sprout and buckwheat sprout |
Also Published As
Publication number | Publication date |
---|---|
KR101282708B1 (en) | 2013-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102189416B1 (en) | Composition for preventing obesity and reducing body fat comprising complex extracts of Inula japonica | |
KR101282708B1 (en) | Composition for Anti-Obesity or Reducing Body Fat, Containg MeJA-Treated Buckwheat Sprout | |
KR20140141274A (en) | Composition for enhancing hair growth or preventing hair loss | |
KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
TW201121559A (en) | Extract of Toona sinensis from supercritical fluid extraction for treating diabetes and metabolic diseases, the preparation method and the use thereof | |
JP2006176436A (en) | Scf expression inhibitor | |
KR101830048B1 (en) | Food composition for improvement obesity or improvement hyperlipidemic with the extract of Terminalia chebula fruit and Phyllanthus emblica | |
KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient | |
KR101491493B1 (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
KR101865142B1 (en) | Pharmaceutical composition containing combination extract of Spiraea prunifolia, Pyrus pyrifolia and Geum japonicum for prevention and treatment of allergic diease | |
KR20190059860A (en) | Composition for Preventing or Treating Pruritus Comprising Natural Extracts | |
KR101796034B1 (en) | Composition for treating obesity comprising fermented steam-dried ginseng berry extract as an active ingredient | |
KR101760163B1 (en) | Composition for anti-obesity comprising extract of Sargassum serratifolium as an effective component | |
KR20220136604A (en) | A pharmaceutical composition for preventing or treating muscle atrophy comprising extract of Salvia plebeia R. Br. or compound derived from the same as an active ingredient | |
EP2762147B1 (en) | Pharmaceutical composition containing puerariae flos extracts as active ingredients for preventing and treating endometriosis | |
US20220023364A1 (en) | Composition for alleviating fatigue or enhancing exercise capability comprising angelica gigas extract, cnidium officinale extract, and paeonia lactiflora extract | |
JP5896618B2 (en) | Melanin production inhibitor | |
KR101754149B1 (en) | Anti-Obesity Food Composition Containing Solidago Virgaurea Extract and Method for Preparing the Same | |
Kim et al. | Inhibition of lipid accumulation by the ethyl acetate fraction of Distylium racemosum in vitro and in vivo | |
CN111465403A (en) | Herbal composition for preventing or treating prostatic hypertrophy | |
KR102149783B1 (en) | Pharmaceutical composition including abeliophyllum distichum extract for inhibiting, preventing, improving or treating liver injury, and health functional food | |
KR102309425B1 (en) | Pharmaceutical Composition Comprising Red Ginseng Oil for Preventing or Treating Prostatic Hyperplasia | |
KR20190099959A (en) | Composition for Preventing, Improving or Treating of muscular disease containing Codium SPP. algae extract | |
JP2017206477A (en) | Myogenesis promoting composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160704 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170908 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180823 Year of fee payment: 6 |
|
R401 | Registration of restoration |